Study identifier:D7700C00001
ClinicalTrials.gov identifier:NCT06311760
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, And Pharmacokinetics of AZD0292 Following Single Ascending Dose Administration to Healthy Participants
Healthy Participants Study
Phase 1
Yes
AZD0292, Placebo
All
32
Interventional
18 Years - 60 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Other
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD0292 Dose 1 Participants will receive single dose of AZD0292 dose 1 as IV infusion on Day 1. | Drug: AZD0292 AZD0292 will be administered as single dose via IV infusion. |
Experimental: AZD0292 Dose 2 Participants will receive single dose of AZD0292 dose 2 as IV infusion on Day 1. | Drug: AZD0292 AZD0292 will be administered as single dose via IV infusion. |
Experimental: AZD0292 Dose 3 Participants will receive single dose of AZD0292 dose 3 as IV infusion on Day 1. | Drug: AZD0292 AZD0292 will be administered as single dose via IV infusion. |
Placebo Comparator: Placebo Participants will receive matching placebo to AZD0292 as IV infusion on Day 1. | Drug: Placebo Placebo will be administered as IV infusion. |